Brokerages Anticipate Pharming Group (PHGUF) Will Announce Quarterly Sales of $18.76 Million
Analysts expect Pharming Group (NASDAQ:PHGUF) to announce sales of $18.76 million for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Pharming Group’s earnings. The lowest sales estimate is $18.19 million and the highest is $19.32 million. Pharming Group reported sales of $3.82 million during the same quarter last year, which indicates a positive year over year growth rate of 391.1%. The company is scheduled to report its next earnings report on Thursday, October 26th.
According to Zacks, analysts expect that Pharming Group will report full-year sales of $18.76 million for the current fiscal year, with estimates ranging from $72.44 million to $75.45 million. For the next fiscal year, analysts anticipate that the business will post sales of $104.19 million per share, with estimates ranging from $95.12 million to $109.77 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that follow Pharming Group.
Separately, Zacks Investment Research upgraded shares of Pharming Group from a “hold” rating to a “buy” rating and set a $1.00 price target for the company in a report on Wednesday.
Shares of Pharming Group (PHGUF) opened at 0.92 on Wednesday. Pharming Group has a 12 month low of $0.17 and a 12 month high of $0.98. The stock’s market cap is $465.17 million.
ILLEGAL ACTIVITY NOTICE: This report was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://www.americanbankingnews.com/2017/10/18/brokerages-anticipate-pharming-group-phguf-will-announce-quarterly-sales-of-18-76-million.html.
Pharming Group Company Profile
Pharming Group NV (Pharming) is a Netherlands-based biotechnology company. The Company operates through two business segments, including Recombinant proteins, and DNage. Pharming focuses on the development, production and commercialization of human therapeutic proteins to be used as innovative therapies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.